Concepedia

Publication | Open Access

Observed Effectiveness of Palivizumab for 29–36-Week Gestation Infants

DOIFull Paper Access

38

Citations

14

References

2016

Year

Harold J. Farber, Frederick J. Buckwold, Barry S. Lachman, J. S. Simpson, Ernest Buck, Matha Arun, Adolfo M. Valadez, Teresa Ruiz, Joy Alonzo, Andrea Henry,
PEDIATRICS

Abstract

Among infants 29 to 32 weeks' gestation without chronic illness, palivizumab use was associated with reduced RSV hospitalizations but increased hospitalizations for bronchiolitis without RSV diagnosis.

References

YearCitations

Page 1